Total Revenue
Amgen Total Revenue decreased by 12.6% to $8.62B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.8%, from $8.15B to $8.62B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows an upward trend with a 9.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates market expansion or higher demand, while a decrease may signal market saturation or competitive pressure.
Detailed definition
Total revenue represents the gross inflow of economic benefits arising from the ordinary operating activities of the com...
Peer comparison
Standard across all public companies; peers in the medical device and diagnostics sector typically show steady growth correlated with product adoption.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.53B | $6.71B | $6.85B | $6.24B | $6.59B | $6.65B | $6.84B | $6.11B | $6.99B | $6.90B | $8.20B | $7.45B | $8.39B | $8.50B | $9.09B | $8.15B | $9.18B | $9.56B | $9.87B | $8.62B |
| QoQ Change | — | +2.8% | +2.1% | -8.9% | +5.7% | +0.9% | +2.8% | -10.7% | +14.4% | -1.2% | +18.7% | -9.1% | +12.6% | +1.4% | +6.9% | -10.3% | +12.6% | +4.1% | +3.2% | -12.6% |
| YoY Change | — | — | — | — | +1.0% | -0.8% | -0.1% | -2.1% | +5.9% | +3.8% | +19.8% | +22.0% | +20.1% | +23.2% | +10.9% | +9.4% | +9.4% | +12.4% | +8.6% | +5.8% |
Product Breakdown — Product sales
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Other products | $1.33B | $1.36B | $1.57B | $1.48B | $1.69B | $1.85B | $2.07B | $1.53B |
| Repatha | — | — | — | — | — | — | — | $876.00M |
| Prolia | $1.17B | $1.05B | $1.17B | $1.10B | $1.12B | $1.14B | $1.05B | $727.00M |
| EVENITY | $391.00M | $399.00M | $431.00M | $442.00M | $518.00M | $541.00M | $599.00M | $562.00M |
| TEPEZZA | $479.00M | $488.00M | $460.00M | $381.00M | $505.00M | $560.00M | $457.00M | $490.00M |
| Otezla | $544.00M | $564.00M | $624.00M | $437.00M | $618.00M | $585.00M | $625.00M | $431.00M |
| BLINCYTO | $264.00M | $327.00M | $381.00M | $370.00M | $384.00M | $392.00M | $413.00M | $415.00M |
| Nplate | $346.00M | $456.00M | $337.00M | $313.00M | $369.00M | $457.00M | $385.00M | $412.00M |
| XGEVA | $562.00M | $541.00M | $561.00M | $566.00M | $532.00M | $539.00M | $447.00M | $411.00M |
| TEZSPIRE | $234.00M | $269.00M | $296.00M | $285.00M | $342.00M | $377.00M | $474.00M | $343.00M |
| KYPROLIS | $377.00M | $378.00M | $372.00M | $324.00M | $378.00M | $359.00M | $351.00M | $330.00M |
| ENBREL | $909.00M | $825.00M | $1.02B | $510.00M | $604.00M | $580.00M | $532.00M | $320.00M |
| Aranesp | $348.00M | $337.00M | $308.00M | $340.00M | $359.00M | $357.00M | $333.00M | $311.00M |
| Vectibix | $270.00M | $282.00M | $246.00M | $267.00M | $305.00M | $284.00M | $319.00M | $287.00M |
| UPLIZNA | — | — | — | — | — | — | — | $262.00M |
| IMDELLTRA/IMDYLLTRA | — | — | — | — | — | — | — | $258.00M |
| KRYSTEXXA | $294.00M | $310.00M | $346.00M | $236.00M | $349.00M | $320.00M | $435.00M | $255.00M |
| Total | $8.39B | $8.50B | $9.09B | $8.15B | $9.18B | $9.56B | $9.87B | $8.62B |
Repatha is derived from annual filings.
Product Breakdown — BeiGene
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 |
|---|---|---|---|---|
| Reportable Segment | $8.15B | $9.18B | $9.56B | $8.62B |
| Total | $8.15B | $9.18B | $9.56B | $8.62B |
Geographic Breakdown
Total Revenue at Other Companies
Frequently Asked Questions
- What is Amgen's total revenue?
- Amgen (AMGN) reported total revenue of $8.62B in Q1 2026.
- How has Amgen's total revenue changed year-over-year?
- Amgen's total revenue increased by 5.8% year-over-year, from $8.15B to $8.62B.
- What is the long-term trend for Amgen's total revenue?
- Over 4 years (2021 to 2025), Amgen's total revenue has grown at a 9.1% compound annual growth rate (CAGR), from $25.98B to $36.75B.
- What does total revenue mean?
- The total amount of money a company brings in from its primary business activities before any expenses.